Chia Tai Tianqing
An April 2025 website announcement identifies TQB3019 as the OAPD platform's first oral BTK PROTAC and reports Chinese clinical authorization.
ChinaFull profile →
Find your next research lead.
All cataloged profiles, sources, filters, and comparisons are open. Sign in to save companies, keep private notes, and join discussions.
471 company identities · 13 technology & service fields
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
74 matching companies
Jing Medicine Technology
The official pipeline explicitly lists HJ-002 and HJ-004 as EGFR PROTACs for NSCLC and advanced cancers, respectively.
ChinaFull profile →
BioDuro
The website lists NanoBRET/TR-FRET/SPR and HiBiT/JESS platforms for permeability, target engagement, ternary complexes, and quantitative degradation kinetics.
United StatesFull profile →
ChemPartner
A dedicated page describes E1/E2/E3 and deubiquitinase assays for the ubiquitin–proteasome system, plus PROTAC evaluation from ternary complexes to degradation kinetics and selectivity.
ChinaFull profile →
Sygnature Discovery
CHARMED provides parallel synthesis with common E3 ligands and linkers, degradation screening, and early ADME. The website identifies an SHP2 degrader collaboration with Japan's UBE.
United KingdomFull profile →
Evotec
An official technical poster describes development of bifunctional degraders using novel E3 ligases and construction of molecular glue libraries.
GermanyFull profile →
Domainex
The website offers CRBN/VHL/IAP degrader design and synthesis, binary / ternary binding, NanoBRET, HiBiT, ubiquitination, and direct-to-biology workflows, and lists a collaboration with Amphista.
United KingdomFull profile →
Reaction Biology
The company explicitly accepts FFS, cost-sharing, and FTE models. Its dedicated page lists validated assays for BRD4, KRAS, CRBN/VHL binding, and ternary complexes.
United StatesFull profile →
Charnwood Discovery
The website explicitly offers PROTAC and molecular glue screening and drug discovery support, describing assay systems for degradation research.
United KingdomFull profile →
Bio-Techne / R&D Systems
A dedicated R&D Systems page explicitly offers custom active-degrader design / synthesis, building-block panels, and E3 ligase development, including a Tocris client case.
United StatesFull profile →
Bristol Myers Squibb
On 2026-08-13, FDA granted accelerated approval to iberdomide (Zenbexus) with daratumumab/hyaluronidase-fihj and dexamethasone for certain previously treated multiple myeloma patients. It is a CRBN-modulating CELMoD.
United StatesFull profile →
Roche
On 2026-06-08, Roche announced joint development and commercialization with Nurix of the oral BTK degrader bexobrutideg (NX-5948), with CLL Phase 3 planned for summer 2026.
SwitzerlandFull profile →
Sanofi
Kymera's Q2 2026 update reports that Sanofi began first-in-human Phase 1 KT-485 (SAR447971), an oral IRAK4 degrader, in June. Sanofi is responsible for subsequent development, regulatory work, and commercialization.
FranceFull profile →
Dialectic Therapeutics
DT2216 is a VHL-recruiting BCL-XL PROTAC. An original 2025 Phase 1 paper in 20 patients reports human PK and peripheral leukocyte BCL-XL reduction. NCI lists combination studies in ovarian and fibrolamellar liver cancers.
United StatesFull profile →
Polymed Biopharmaceuticals (Hangzhou)
An original joint announcement with Photys on 2026-08-13 reports Phase 1 healthy-volunteer dosing of HPB-143/PHT-776. Polymed licensed development and commercialization rights outside Greater China and Southeast Asia to Photys.
ChinaFull profile →
Pfizer
An original Nurix announcement on 2026-09-29 reports a research milestone in the Pfizer DAC collaboration. Pfizer handles antibody conjugation and subsequent development. Global vepdegestrant development, manufacturing, and commercialization rights transferred to Rigel in June 2026.
United StatesFull profile →
Eli Lilly and Company
Lilly's website lists LY4584180 as an oral, monovalent BCL6 polymerizing molecular glue. Phase 1 NOVA-BCL6-1, NCT07226843, is recruiting; UCSF's trial page records an April 2026 start.
United StatesFull profile →
Aurigene Pharmaceutical Services
A dedicated official page offers PROTAC and partial-PROTAC synthesis, E3 ligand / linker design, molecular glues, ternary-complex and cellular degradation evaluation, and custom ADME/PK and toxicology services, through standalone or integrated projects.
IndiaFull profile →
Enamine
The official custom synthesis page explicitly lists molecular glue libraries and bifunctional compounds including PROTACs, with FTE quotations and IP-sensitive work under confidentiality agreements.
Almac Discovery
Almac Discovery's current official pipeline lists an oral GSPT1 molecular glue and a GSPT1 degrader–antibody conjugate, both preclinical. DAC payloads are used in HER2/CD33-targeted constructs.
United KingdomFull profile →
Eurofins Discovery
The group website lists TPD as a CRO service. Custom offerings explicitly cover target engagement, modulation, and degradation, plus custom proteins, cell lines, and assay development.
Charles River Laboratories
The website explicitly offers PROTAC and molecular glue screening, including HiBiT, proteomics, ternary-complex structures, ADME/DMPK, in vivo formulations, and safety services.
United StatesFull profile →
Nuvisan
An official page explicitly offers ligand / linker design, ternary-complex prediction, mechanism / selectivity evaluation, DMPK, early CMC, solubility, crystallization, and formulation strategies.
GermanyFull profile →
Selvita
The service page covers target / E3 ligand discovery, linker optimization, SPR/ITC, ubiquitination and degradation assays, and custom ADME and PBPK modeling.
PolandFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.